Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.61 |
| ▸ | RAB9A | P51151 | 4/20 | 0.61 |
| ▸ | NPC1 | O15118 | 3/20 | 0.61 |
| ▸ | CASP3 | P42574 | 1/20 | 0.61 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.61 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.61 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.61 |
| ▸ | PIK3CD | O00329 | 5/20 | 0.49 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.49 |
| ▸ | PIK3CB | P42338 | 5/20 | 0.49 |
| ▸ | PIK3CG | P48736 | 5/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | GAA | P10253 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.45 |
| ▸ | RELA | Q04206 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2397832 | 0.80 | MEN1 (0.61) | MEN1KMT2ARAB9ANPC1PIK3CD | |
| SCHEMBL2395755 | 0.78 | MEN1 (0.60) | MEN1KMT2ARAB9ANPC1CASP3 | |
| SCHEMBL48710 | 0.76 | PIK3CG (0.82) | MEN1KMT2ARAB9ANPC1CASP3 | |
| SCHEMBL2395369 | 0.76 | MEN1 (0.64) | MEN1KMT2ARAB9ANPC1CASP3 | |
| SCHEMBL2832331 | 0.75 | ALDH1A1 (0.59) | MEN1KMT2ARAB9ANPC1CASP3 | |
| SCHEMBL2396380 | 0.73 | PIK3CD (0.62) | MEN1KMT2APIK3CDPIK3CAPIK3CB | |
| SCHEMBL1886940 | 0.73 | NPC1 (0.39) | MEN1KMT2ARAB9ANPC1CASP3 | |
| SCHEMBL3601760 | 0.73 | MEN1 (0.63) | MEN1KMT2ARAB9ANPC1CASP3 | |
| SCHEMBL2396657 | 0.72 | MEN1 (0.54) | MEN1KMT2ARAB9ANPC1CASP3 | |
| SCHEMBL2396778 | 0.70 | PIK3CD (0.68) | PIK3CDPIK3CAPIK3CBPIK3CGMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8017608-B2 | 5-Phenylthiazole derivatives and their use as p13 kinase inhibitors | NOVARTIS AG (CH) | 2011-09-13 | — | — | US | disclosed |
| CN-100569770-C | 5-phenyl thiazole derivant and they purposes as the PI3 kinase inhibitor | NOVARTIS AG (CH) | 2009-12-16 | — | — | CN | disclosed |
| EP-1608647-B1 | 5-PHENYLTHIAZOLE DERIVATIVES AND THEIR USE AS P13 KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-01-09 | — | — | EP | disclosed |
| US-20060148822-A1 | 5-Phenylthiazole derivatives and their use as p13 kinase inhibitors | NOVARTIS AG (CH) | 2006-07-06 | — | — | US | disclosed |
| CN-1780832-A | 5-phenylthiazole derivatives and their use as PI3 kinase inhibitors | NOVARTIS AG (CH) | 2006-05-31 | — | — | CN | disclosed |
| EP-1608647-A1 | 5-PHENYLTHIAZOLE DERIVATIVES AND THEIR USE AS P13 KINASE INHIBITORS | Novartis AG (CH) | 2005-12-28 | — | — | EP | disclosed |
| WO-2004078754-A1 | 5-PHENYLTHIAZOLE DERIVATIVES AND THEIR USE AS P13 KINASE INHIBITORS | NOVARTIS AG (CH) | 2004-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148822-A1 | 5-Phenylthiazole derivatives and their use as p13 kinase inhibitors | MAP3K13, AKT3, MAP3K3 | MEN1 1758/4885KMT2A 2160/4885RAB9A 1020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.